简介：美国塞瓦基金会成立于1978年，创始人是一群美国医生，为非政府、非宗教、非盈利性的民间慈善组织。主要工作领域：健康、助残，致力于改善落后地区的医疗卫生状况和经济条件。是“视觉2020：享有看得见的权利”的协作成员之一。

简介：我国著名眼科学家、中国共产党党员、国务院政府特殊津贴获得者、四川大学华西医院眼科罗成仁教授因病不幸于2014年7月3日4时19分逝世，享年91岁。

简介：AIM:Tocomparetheregularityandaccuracyoflaserinsitukeratomileusis(LASIK)flapscreatedbytheZiemerFEMTOLDV'Classic'(Ziemer'Classic')andZiemerFEMTOLDVCrystalLinefemtosecondlaser(ZiemerCrystalLine).METHODS:Fourier-domainopticalcoherencetomography(RTVueOCT)wasusedtomeasurethemorphologyof200LASIKflapsof100consecutivepatientscreatedwiththeZiemerClassic(100flaps)ortheZiemerCrystalLine(100flaps)atoneweekpostoperatively.Flapthicknesswasevaluatedat36specifiedmeasurementpointsoneachflap.Forallprocedureswithbothlasers,thenominalflapthicknesswas110μm.RESULTS:ThemeanflapthicknessoftheZiemerCrystalLinegroup(102.49±2.68μm)wasthinnerthanthatoftheZiemerClassicgroup(107.65±5.09μm)(P<0.01).Averagethicknessofallflapswasuniformwithin4μmatallmeasurementpoints.TheflapsintheZiemerCrystalLinegroupweremoreregularthanthoseintheZiemerClassicgroupwhenmeasuredfromthecentertotheperiphery.Themaximumdeviationfromthenominal110μmof36measurementswas8μmintheZiemerClassicgroup,whileintheZiemerCrystalLinegroupitwas9μm.Withinthe3600measurementsonthe100eyes,differencesgreaterthan20μmwereobserved0.14%intheZiemerClassicgroup,and0.04%intheZiemerCrystalLinegroup.CONCLUSION:TheflapscreatedwiththeZiemerFEMTOLDVCrystalLinefemtosecondlaseraremoreuniformandthinnerthanthosecreatedbytheZiemerFEMTOLDVClassicfemtosecondlaser.

简介：AIM:Topresenttheoutcomeofmodifiedgridlaserphotocoagulation(GLP)indiffusediabeticmacularedema(DDME)ineyeswithoutextrafovealand/orvitreofovealtraction.METHODS:InclusioncriteriafortheretrospectivestudywereDDMEeyesofpatientswithtypeⅡdiabetesmellitusthathad≥4monthsoffollow-upfollowingGLP.Onlyoneeyeperpatientwasanalyzed.Using3-Dspectral-domainopticalcoherencetomography(3-DSDOCT),eyesthathadeitherextrafovealorvitreofovealtraction,orhadbeenpreviouslytreatedbyanintravitrealmedication(s)wereexcluded.TreatedDDMEeyesweredividedinto4groups:A)'Classic'DDMEthatinvolvedthecentralmacula;B)edemadidnotinvolvethemacularcenter;C)eyesassociatedwithcentralepiretinalmembrane(ERM);D)DDMEthatwasassociatedwithmacularcapillarydropout≥2disc-diameter(DD).RESULTS:GLPoutcomein35DDMEeyesafter4-24(mean,13.1±6.9)monthswasasfollows:GroupA)18eyeswith'classic'DDME.Followingoneor2(mean,1.2)GLPtreatments,best-correctedvisualacuity(BCVA)improvedby1-2Snellenlinesin44.4%(8/18)ofeyes,andworsenedby1linein11.1%(2/18).Centralmacularthickness(CMT)improvedby7%-49%(mean,26.6%)in77.8%(14/18)ofeyes.CausesofCMTworsening(n=4)werecommonlyexplainable,predominantly(n=3)associatedwithemergenceofextrafovealtraction,5-9monthspost-GLP.GroupB)GLP(s)inDDMEthatdidnotinvolvethemacularcenter(n=6)resultedinimprovedBCVAby1-2linesin2eyes.However,thecentralmaculabecameinvolvedintheedemaprocessaftertheGLPin3(50%)eyes,associatedwithanemergenceofextrafovealtractioninoneoftheseeyes4monthsfollowingtheGLP.GroupC)GLPfailedinall5eyesassociatedwithcentralERM.GroupD)GLPwasofpartialbenefitin2of6treatedeyeswithmacularcapillarydropout≥2DD.CONCLUSION:EyeswithDDMEthatinvolvedthemacularcenterwerefoundtoachievefavourableoutcomesafterGLP(s)duringmid-termfollow-up,unlesscomplicatedpre-GLPorpost-GLPbyvltreoretinalinterfaceabnormalities,oftenextrafovealtra